Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GT Biopharma (GTBP) Short term Debt (2016 - 2021)

GT Biopharma (GTBP) has disclosed Short term Debt for 12 consecutive years, with $340000.0 as the latest value for Q3 2021.

  • On a quarterly basis, Short term Debt fell 98.52% to $340000.0 in Q3 2021 year-over-year; TTM through Sep 2021 was $340000.0, a 98.52% decrease, with the full-year FY2020 number at $384000.0, down 97.09% from a year prior.
  • Short term Debt was $340000.0 for Q3 2021 at GT Biopharma, down from $842000.0 in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $23.0 million in Q3 2020 to a low of $340000.0 in Q3 2021.
  • A 5-year average of $8.2 million and a median of $8.7 million in 2018 define the central range for Short term Debt.
  • Peak YoY movement for Short term Debt: surged 712.32% in 2018, then crashed 98.52% in 2021.
  • GT Biopharma's Short term Debt stood at $844000.0 in 2017, then soared by 1155.57% to $10.6 million in 2018, then increased by 24.63% to $13.2 million in 2019, then tumbled by 97.09% to $384000.0 in 2020, then fell by 11.46% to $340000.0 in 2021.
  • Per Business Quant, the three most recent readings for GTBP's Short term Debt are $340000.0 (Q3 2021), $842000.0 (Q2 2021), and $362000.0 (Q1 2021).